Skip to main content
NCBI home page
British Medical Journal (Clinical Research Ed.) logoLink to British Medical Journal (Clinical Research Ed.)
. 1982 Feb 20;284(6315):537–539. doi: 10.1136/bmj.284.6315.537

Treatment of hypertension with ketanserin, a new selective 5-HT2 receptor antagonist.

G J Wenting, A J Man in 't Veld, A J Woittiez, F Boomsma, M A Schalekamp
PMCID: PMC1496107  PMID: 6800533

Abstract

The new selective 5-HT2 receptor blocking agent ketanserin was given in a dose of 10 mg intravenously to 12 patients with essential hypertension. It caused a distinct fall in supine systemic arterial, right atrial, pulmonary artery, and pulmonary capillary "wedge" pressures. Cardiac output, renal blood flow, and glomerular filtration rate showed no persistent changes. Thus 5-HT2 receptor blockade caused dilatation of both resistance and capacitance vessels and of the renal vascular bed. Heart rate and plasma concentrations of renin and noradrenaline rose after ketanserin. These data suggest that 5-HT may have a role in maintaining high blood pressure.

Full text

PDF
537

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. De Cree J., Verhaegen H., Symoens J. Acute blood-pressure-lowering effect of ketanserin. Lancet. 1981 May 23;1(8230):1161–1162. doi: 10.1016/s0140-6736(81)92331-x. [DOI] [PubMed] [Google Scholar]
  2. Demoulin J. C., Bertholet M., Soumagne D., David J. L., Kulbertus H. E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet. 1981 May 30;1(8231):1186–1188. doi: 10.1016/s0140-6736(81)92352-7. [DOI] [PubMed] [Google Scholar]
  3. Derkx F. H., von Gool J. M., Wenting G. J., Verhoeven R. P., Man in 't Veld A. J., Schalekamp M. A. Inactive renin in human plasma. Lancet. 1976 Sep 4;1(7984):496–499. doi: 10.1016/s0140-6736(76)90791-1. [DOI] [PubMed] [Google Scholar]
  4. Henry D. P., Starman B. J., Johnson D. G., Williams R. H. A sensitive radioenzymatic assay for norepinephrine in tissues and plasma. Life Sci. 1975 Feb 1;16(3):375–384. doi: 10.1016/0024-3205(75)90258-1. [DOI] [PubMed] [Google Scholar]
  5. Henry P. D., Yokoyama M. Supersensitivity of atherosclerotic rabbit aorta to ergonovine. Mediation by a serotonergic mechanism. J Clin Invest. 1980 Aug;66(2):306–313. doi: 10.1172/JCI109858. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Kuhn D. M., Wolf W. A., Lovenberg W. Review of the role of the central serotonergic neuronal system in blood pressure regulation. Hypertension. 1980 May-Jun;2(3):243–255. doi: 10.1161/01.hyp.2.3.243. [DOI] [PubMed] [Google Scholar]
  7. Leysen J. E., Awouters F., Kennis L., Laduron P. M., Vandenberk J., Janssen P. A. Receptor binding profile of R 41 468, a novel antagonist at 5-HT2 receptors. Life Sci. 1981 Mar 2;28(9):1015–1022. doi: 10.1016/0024-3205(81)90747-5. [DOI] [PubMed] [Google Scholar]
  8. Peroutka S. J., Snyder S. H. Multiple serotonin receptors: differential binding of [3H]5-hydroxytryptamine, [3H]lysergic acid diethylamide and [3H]spiroperidol. Mol Pharmacol. 1979 Nov;16(3):687–699. [PubMed] [Google Scholar]
  9. Schalekamp M. A., Schalekamp-Kuyken M. P., Birkenhäger W. H. Abnormal renal haemodynamics and renin suppression in hypertensive patients. Clin Sci. 1970 Jan;38(1):101–110. doi: 10.1042/cs0380101. [DOI] [PubMed] [Google Scholar]
  10. Van Nueten J. M., Janssen P. A., Van Beek J., Xhonneux R., Verbeuren T. J., Vanhoutte P. M. Vascular effects of ketanserin (R 41 468), a novel antagonist of 5-HT2 serotonergic receptors. J Pharmacol Exp Ther. 1981 Jul;218(1):217–230. [PubMed] [Google Scholar]

Articles from British Medical Journal (Clinical research ed.) are provided here courtesy of BMJ Publishing Group

RESOURCES